Search
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing
Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnIt is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries … It is available in the form of a 5% amorolfine nail lacquer used to treat onychomycosis (fungal infection of the toe- and fingernails).
Coronary artery thrombosis
go.drugbank.com/conditions/DBCOND0007525Drugs: AtorvastatinSynonyms: Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarctionDiabetic Retinopathy (DR)
go.drugbank.com/conditions/DBCOND0118126Synonyms: Retinopathy co-occurrent and due to diabetes mellitusOphthalmia Neonatorum
go.drugbank.com/conditions/DBCOND0000276Drugs: ErythromycinSynonyms: Neonatal conjunctivitis and dacryocystitisUndescended Testis
go.drugbank.com/conditions/DBCOND0033671Synonyms: Undescended and ectopic testicleMirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigational[L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).
Categories: Antineoplastic and Immunomodulating AgentsSynonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDENaftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum … , Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] It blocks neuromuscular transmission by cleaving SNAP-25, producing partial chemical denervation and a localized reduction in muscle activity. … [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries
Categories: Enzymes and Coenzymes, Amino Acids, Peptides, and ProteinsBromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.